--- title: "Sagimet Biosciences (SGMT) news: offering" url: "https://aibio.space/companies/sagimet-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SGMT offering news: Sagimet expects cash and $115 million offering to fund operations to mid-2029. Sagimet Biosciences Inc. (NASDAQ: SGMT), United States." --- SGMT Sagimet Biosciences Inc. NASDAQ · United States # Sagimet Biosciences (SGMT) news SGMT offering news Financings · 2026-10-22 ## [Sagimet expects cash and $115 million offering to fund operations to mid-2029](https://aibio.space/news/sagimet-expects-cash-115-million-offering-fund-operations-mid-2029/) Sagimet's investor presentation says $257.6 million in cash, cash equivalents and marketable securities at June 30, 2026, plus a $115 million underwritten offering completed in September, should fund operations to mid-2029. The presentation does not name the underwriters. ## Latest Sagimet Biosciences news We have not published a story on Sagimet Biosciences yet. When there is news, it will appear here. ## Sagimet Biosciences at a glance - **Ticker**: SGMT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $240.1 million ### Related companies - [Savara](https://aibio.space/companies/savara/) NASDAQ: SVRA - [Onconetix](https://aibio.space/companies/onconetix/) NASDAQ: ONCO - [Mirum Pharmaceuticals](https://aibio.space/companies/mirum-pharmaceuticals/) NASDAQ: MIRM - [Panbela Therapeutics](https://aibio.space/companies/panbela-therapeutics/) OTC: PBLA - [Braveheart Bio](https://aibio.space/companies/braveheart-bio/) NASDAQ: BRVE - [Supernus Pharmaceuticals](https://aibio.space/companies/supernus-pharmaceuticals/) NASDAQ: SUPN - [Organon & Co.](https://aibio.space/companies/organon/) NYSE: OGN - [Aprea Therapeutics](https://aibio.space/companies/aprea-therapeutics/) NASDAQ: APRE ### Also on NASDAQ - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) VERA - [Arrowhead Pharmaceuticals](https://aibio.space/companies/arrowhead-pharmaceuticals/) ARWR - [CytoMed Therapeutics](https://aibio.space/companies/cytomed-therapeutics/) GDTC - [Vericel](https://aibio.space/companies/vericel/) VCEL - [Neuphoria Therapeutics](https://aibio.space/companies/neuphoria-therapeutics/) NEUP - [Dianthus Therapeutics](https://aibio.space/companies/dianthus-therapeutics/) DNTH ## Sagimet Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$39.1 million](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026140/) | [$38.4 million](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026140/) | | Net income (loss) | [-$51.0 million](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026140/) | [-$45.6 million](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026140/) | | Cash from operations | [-$45.6 million](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026140/) | [-$42.4 million](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026140/) | | Cash and equivalents | [$35.0 million](https://www.sec.gov/Archives/edgar/data/1400118/000119312526343441/) | [$75.8 million](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026140/) | | Short-term investments | [$78.1 million](https://www.sec.gov/Archives/edgar/data/1400118/000119312526343441/) | [$75.4 million](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026140/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $165.9 million, plus short-term investments of $74.2 million, $240.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Sagimet Biosciences Has Sagimet Biosciences raised money recently? Our latest story on this, dated Oct 22, 2026: "Sagimet expects cash and $115 million offering to fund operations to mid-2029". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sagimet-expects-cash-115-million-offering-fund-operations-mid-2029/). What is the ticker symbol of Sagimet Biosciences? Sagimet Biosciences Inc. trades under the ticker SGMT on NASDAQ. Where is Sagimet Biosciences listed? Sagimet Biosciences Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0O2. What is the SEC CIK of Sagimet Biosciences? The SEC Central Index Key (CIK) for Sagimet Biosciences Inc. is 1400118. Its filings are on SEC EDGAR. How many shares does Sagimet Biosciences have outstanding? 30,674,855 shares as of 2024-11-08, per the cover page of its 10-Q filed 2024-11-14. Which country or territory is Sagimet Biosciences listed under? Our directory records Sagimet Biosciences Inc. under United States. What does Sagimet Biosciences do? Our directory classifies Sagimet Biosciences Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Sagimet Biosciences? The ISIN recorded for Sagimet Biosciences Inc. is US7867001049. Does aibio.space cover Sagimet Biosciences? aibio.space lists Sagimet Biosciences Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Sagimet Biosciences incorporated? SEC records list its state or country of incorporation as DE. Is Sagimet Biosciences profitable? Sagimet Biosciences Inc. reported a net loss of $51.0 million for the fiscal year ended Dec 31, 2025, and used $45.6 million of cash in operations, per its annual report to the SEC. How much does Sagimet Biosciences spend on research and development? $39.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Sagimet Biosciences have? $240.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Sagimet Biosciences (SGMT) stock news? Our latest story on Sagimet Biosciences, dated Oct 22, 2026: "Sagimet expects cash and $115 million offering to fund operations to mid-2029". Sagimet's investor presentation says $257.6 million in cash, cash equivalents and marketable securities at June 30, 2026, plus a $115 million underwritten offering completed in September, should fund operations to mid-2029. The presentation does not name the underwriters. [Source](https://aibio.space/news/sagimet-expects-cash-115-million-offering-fund-operations-mid-2029/). How long will Sagimet Biosciences's cash last? From our story of Oct 22, 2026: The company expects topline results in 2H 2027, which falls before the mid-2029 date the company gives for its cash runway. [Source](https://aibio.space/news/sagimet-expects-cash-115-million-offering-fund-operations-mid-2029/). ## Investor discussion: Sagimet Biosciences Members talk about Sagimet Biosciences (SGMT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Sagimet Biosciences, newest first. Each line links the filing it comes from. 1. 2026-10-22 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1400118/000119312526428314/d124492dex991.htm) 2. 2026-09-30 Financings Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/d96035dex991.htm) 3. 2026-07-21 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1400118/000119312526309334/d141539dex991.htm) 4. 2026-04-27 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1400118/000110465926049015/tm2612794d1_ex99-1.htm) 5. 2025-08-22 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1400118/000110465925081630/tm2524100d1_8k.htm) 6. 2025-08-14 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1400118/000110465925078746/tm2523529-1_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SGMT on TradingView](https://www.tradingview.com/symbols/NASDAQ-SGMT/). ## SEC filings and registration - **SEC name**: Sagimet Biosciences Inc. - **CIK**: 1400118 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SGMT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 950 TOWER LANE, FOSTER CITY, CA, 94404 - **Phone**: (650) 561-8600 - **Shares outstanding**: 30,674,855 as of 2024-11-08 (10-Q filed 2024-11-14) - **Former names**: 3-V Biosciences, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1400118/000119312526428314/d124492d8k.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1400118/000119312526409335/d136610d8k.htm) filed 2026-10-01 - [424B5](https://www.sec.gov/Archives/edgar/data/1400118/000119312526409325/d68394d424b5.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/d96035d8k.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1400118/000119312526347854/d150919d8k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/d36435d8k.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1400118/000119312526343441/sgmt-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1400118/000119312526309334/d141539d8k.htm) filed 2026-07-21 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001400118), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Sagimet Biosciences Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SGMT, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Sagimet Biosciences Inc. - **Ticker**: SGMT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US7867001049 - **Other listed symbols**: GETTEX:0O2 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SGMT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/sagimet-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sagimet Biosciences (SGMT) news: offering", 2026-10-31, https://aibio.space/companies/sagimet-biosciences/